Fig. 3From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysisForest plots of ORR (a) and DCR (b) associated with pazopanib versus sunitinibBack to article page